Chromogranin-A as a Serum Marker for Neuroendocrine Tumors: Comparison with Neuron-Specific Enolase and Correlation with Immunohistochemical Findings
Open Access
- 1 July 1999
- journal article
- research article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 14 (3) , 160-166
Abstract
Background: Chromogranin-A (Cg-A) is a 439-amino-acid protein contained in secretory granules of neuroendocrine cells, in addition to specific hormone peptides or neuropeptides. Since Cg-A is co-released with peptide hormones its serum concentration can be used as a marker of neuroendocrine tumors. Aim: Evaluation of the analytical performance of a new IRMA method for Cg-A assay and of the clinical value of serum Cg-A and neuron-specific enolase (NSE) in neuroendocrine tumors. In addition, we compared the diagnostic usefulness of both Cg-A and NSE serum levels and their relationship to tissue expression. Patients and methods: Initially we evaluated the analytical performance (intra- and interassay imprecision, dilution test and detection limit) of the Cg-A RIACT method (CIS Bio-International, Gifsur-Yvette, France). We selected 50 patients affected by various histologically confirmed neuroendocrine tumors (NETs): 111In-pentetreotide scan and helical computed tomography were employed to assess tumor extent. Cg-A and NSE were measured before surgery in serum samples of patients and 50 age-matched controls by IRMA methods. After surgery immunohistochemical stains for Cg-A and NSE were performed on surgical specimens of tumor tissue. Results: Cg-A levels were significantly higher (p<0.0001) in patients with NETs than in healthy controls and we found a positive correlation between serum and tissue expression (p<0.05). Serum levels of Cg-A were also related to tumor extent (p<0.05) but in some cases we observed significant elevation of serum Cg-A in small, intensely immunoreactive NETs. ROC curve analysis showed better accuracy for serum Cg-A compared to NSE in the diagnosis of NETs, while no significant relationship was found between serum expression and immunostaining for NSE. Discussion: Our results confirmed the biological and clinical significance of circulating Cg-A as an expression of granular content in neuroendocrine tissues and supported the complementary usefulness of serum Cg-A in the diagnosis and evaluation of NETs together with imaging modalities.Keywords
This publication has 19 references indexed in Scilit:
- Chromogranin A: its clinical value as marker of neuroendocrine tumoursEuropean Journal of Clinical Investigation, 1998
- Serum chromogranin A in the differential diagnosis of Cushing's syndromeEuropean Journal of Endocrinology, 1994
- The granin protein family: Markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumorsJournal of Endocrinological Investigation, 1994
- Chromogranin A: Its Role in Endocrine Function and as an Endocrine and Neuroendocrine Tumor Marker*Endocrine Reviews, 1991
- Chromostatin, a 20-amino acid peptide derived from chromogranin A, inhibits chromaffin cell secretion.Proceedings of the National Academy of Sciences, 1991
- Synaptophysin and chromogranins/secretogranins widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosisVirchows Archiv B Cell Pathology Including Molecular Pathology, 1989
- Hormone-Negative, Chromogranin a-Positive Endocrine TumorsNew England Journal of Medicine, 1989
- THE SEQUENCE OF PORCINE CHROMOGRANIN A MESSENGER RNA DEMONSTRATES CHROMOGRANIN A CAN SERVE AS THE PRECURSOR FOR THE BIOLOGICALLY ACTIVE HORMONE, PANCREASTATINEndocrinology, 1988
- Proteolytic processing of chromogranin A in purified insulin granules. Formation of a 20 kDa N-terminal fragment (betagranin) by the concerted action of a Ca2+-dependent endopeptidase and carboxypeptidase H (EC 3.4.17.10)Biochemical Journal, 1987
- Secretion of Chromogranin A by Peptide-Producing Endocrine NeoplasmsNew England Journal of Medicine, 1986